Physician

Richard Francis Mcdonough, M.D.

According to 2025 Medicare claims, Richard Mcdonough, M.D. (NPI: 1659354694) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Pasco, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33541-1314.

Mcdonough's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 521 traditional Medicare patients, billed 151,585 HCPCS/CPT codes, and received $3,117,068 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 718 prescription claims across 232 beneficiaries totaling $1,233,178 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2018 DME data shows 28 claims. Open Payments data shows 187 records totaling $33,614. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have fallen sharply in recent years, from $1,613,820 to $1,233,178. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	823	231,498	$1,966,377
2016	900	186,649	$2,324,926
2017	859	167,218	$2,003,312
2018	786	112,216	$1,415,517
2019	826	127,540	$1,377,336
2020	699	155,172	$1,653,798
2021	680	120,283	$1,282,513
2022	546	115,795	$1,634,843
2023	503	140,979	$2,381,554
2024	521	151,585	$3,117,068

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	300	1,672	$1,613,820
2016	298	1,671	$2,405,485
2017	265	1,170	$2,631,147
2018	282	1,362	$3,598,608
2019	278	1,326	$3,470,533
2020	305	1,287	$3,986,992
2021	303	1,172	$3,377,389
2022	310	1,106	$4,042,228
2023	254	827	$1,262,924
2024	232	718	$1,233,178

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	34	174	$15,894
2016	N/R	56	$4,511
2017	N/R	68	$13,850
2018	N/R	28	$255
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	328	847	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	142	209	$68
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	96	121	$13
36415	Insertion of needle into vein for collection of blood sample	347	1,180	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	339	1,237	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	12	360	$204,886
Brukinsa	Zanubrutinib	20	600	$145,668
Xarelto	Rivaroxaban	33	2,130	$37,516
Eliquis	Apixaban	22	1,290	$24,743
Anastrozole	Anastrozole	132	11,590	$4,360

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	187	$33,614	Rigel Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Richard Francis Mcdonough, M.D.?

Tedicare shows public-source Medicare data for Richard Francis Mcdonough, M.D. (NPI 1659354694), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Richard Francis Mcdonough, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Richard Francis Mcdonough, M.D.?

Richard Francis Mcdonough, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Richard Francis Mcdonough, M.D. have Open Payments data?

Richard Francis Mcdonough, M.D. has 187 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.